$11.8 Billion is the total value of Baker Brothers Advisors's 114 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 44.4% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ABLX | Sell | Ablynx NVsponsored adr | $118,766,000 | +14.2% | 2,176,802 | -47.7% | 1.01% | +11.8% |
NBIX | Sell | Neurocrine Biosciences, Inc. | $78,338,000 | +0.5% | 944,624 | -6.0% | 0.66% | -1.8% |
SGMO | Sell | Sangamo Therapeutics, Inc. | $30,544,000 | -11.9% | 1,607,579 | -23.9% | 0.26% | -13.7% |
BLCM | Sell | Bellicum Pharmaceuticals, Inc. | $27,234,000 | -35.7% | 4,151,578 | -17.5% | 0.23% | -37.1% |
EXEL | Sell | Exelixis, Inc. | $25,753,000 | -43.8% | 1,162,644 | -22.8% | 0.22% | -45.1% |
NTLA | Sell | Intellia Therapeutics, Inc. | $17,585,000 | -20.1% | 833,795 | -27.2% | 0.15% | -22.0% |
PGNX | Sell | Progenics Pharmaceuticals, Inc. | $17,204,000 | -8.2% | 2,306,184 | -26.8% | 0.15% | -9.9% |
MYOK | Sell | MyoKardia, Inc. | $14,165,000 | -5.3% | 290,264 | -18.3% | 0.12% | -7.7% |
AERI | Sell | Aerie Pharmaceuticals, Inc. | $11,699,000 | -34.6% | 215,655 | -28.0% | 0.10% | -36.1% |
CPRX | Sell | Catalyst Pharmaceuticals, Inc. | $10,471,000 | -54.2% | 4,381,072 | -25.1% | 0.09% | -55.1% |
ASMB | Sell | Assembly Biosciences, Inc. | $9,523,000 | -34.8% | 193,787 | -40.0% | 0.08% | -36.2% |
ANAB | Sell | AnaptysBio, Inc. | $9,480,000 | -48.1% | 91,086 | -49.8% | 0.08% | -49.4% |
FOMX | Sell | Foamix Pharmaceuticals Ltd. | $8,203,000 | -44.7% | 1,598,991 | -35.2% | 0.07% | -45.3% |
ALKS | Sell | Alkermes plc | $5,811,000 | -29.3% | 100,251 | -33.3% | 0.05% | -31.0% |
STML | Sell | Stemline Therapeutics, Inc. | $4,404,000 | -55.4% | 287,827 | -54.6% | 0.04% | -57.0% |
NLNK | Sell | NewLink Genetics Corporation | $3,678,000 | -55.0% | 507,273 | -49.6% | 0.03% | -56.3% |
OVID | Sell | Ovid Therapeutics Inc. | $1,751,000 | -46.8% | 247,733 | -25.7% | 0.02% | -48.3% |
SNSS | Sell | Sunesis Pharmaceuticals, Inc. | $1,514,000 | -44.7% | 556,665 | -24.9% | 0.01% | -45.8% |
SELB | Sell | Selecta Biosciences, Inc. | $955,000 | -65.7% | 93,750 | -67.0% | 0.01% | -66.7% |
AKTX | Sell | Akari Therapeutics, Plcsponsored adr | $618,000 | -79.5% | 339,833 | -51.2% | 0.01% | -80.8% |
TENX | Exit | Tenax Therapeutics, Inc. | $0 | – | -348,374 | -100.0% | -0.00% | – |
NVIV | Exit | InVivo Therapeutics Holdings Corp. | $0 | – | -331,393 | -100.0% | -0.00% | – |
FPRX | Exit | Five Prime Therapeutics, Inc. | $0 | – | -19,247 | -100.0% | -0.00% | – |
RTTR | Exit | Ritter Pharmaceuticals, Inc. | $0 | – | -2,800,000 | -100.0% | -0.01% | – |
AKAOQ | Exit | Achaogen, Inc. | $0 | – | -122,482 | -100.0% | -0.01% | – |
KPTI | Exit | Karyopharm Therapeutics Inc. | $0 | – | -216,990 | -100.0% | -0.02% | – |
Exit | Protalix BioTherapeutics, Inc.note 4.5% 9/15/2018 | $0 | – | -3,423,000 | -100.0% | -0.02% | – | |
EPZM | Exit | Epizyme, Inc. | $0 | – | -232,481 | -100.0% | -0.02% | – |
ACOR | Exit | Acorda Therapeutics, Inc. | $0 | – | -205,966 | -100.0% | -0.04% | – |
AAAP | Exit | Advanced Accelerator Applications S.A.sponsored ads | $0 | – | -55,125 | -100.0% | -0.04% | – |
AGIO | Exit | Agios Pharmaceuticals, Inc. | $0 | – | -128,666 | -100.0% | -0.06% | – |
ITCI | Exit | Intra-Cellular Therapies, Inc. | $0 | – | -609,166 | -100.0% | -0.08% | – |
LGND | Exit | Ligand Pharmaceuticals Incorporated | $0 | – | -73,386 | -100.0% | -0.09% | – |
IMGN | Exit | ImmunoGen, Inc. | $0 | – | -2,563,489 | -100.0% | -0.14% | – |
Exit | Acorda Therapeutics, Inc.note 1.75% 6/15/2021 | $0 | – | -35,083,000 | -100.0% | -0.26% | – | |
RXDX | Exit | Ignyta, Inc. | $0 | – | -1,384,266 | -100.0% | -0.32% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Incyte Corporation | 42 | Q3 2023 | 37.6% |
ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
Cerus Corporation | 42 | Q3 2023 | 0.9% |
Insmed Incorporated | 42 | Q3 2023 | 0.4% |
Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
Verastem, Inc. | August 10, 2023 | ? | ? |
ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
Merus N.V. | February 14, 2023 | ? | ? |
Surrozen, Inc./DE | February 14, 2023 | 833,333 | 2.3% |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
4 | 2024-04-23 |
SC 13D/A | 2024-04-23 |
4 | 2024-04-22 |
3 | 2024-04-18 |
SC 13D | 2024-04-18 |
3 | 2024-04-01 |
4 | 2024-04-01 |
4 | 2024-04-01 |
4 | 2024-04-01 |
SC 13D | 2024-04-01 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.